Cargando…
Fuzheng Kang’ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial
BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. Chinese herbal medicine (CHM) has been used as a complementary therapy for cancer for deca...
Autores principales: | Yang, Xiao-Bing, Wu, Wan-yin, Long, Shun-qin, Deng, Hong, Pan, Zong-Qi, He, Wen-Feng, Zhou, Yu-Shu, Liao, Gui-Ya, Li, Qiu-Ping, Xiao, Shu-Jing, Cai, Jiao-Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396173/ https://www.ncbi.nlm.nih.gov/pubmed/25873045 http://dx.doi.org/10.1186/s13063-015-0685-2 |
Ejemplares similares
-
GPX4 Plays a Crucial Role in Fuzheng Kang’ai Decoction-Induced Non-Small Cell Lung Cancer Cell Ferroptosis
por: Zhao, Yue-Yang, et al.
Publicado: (2022) -
Fuzheng Kang-Ai decoction enhances the effect of Gefitinib-induced cell apoptosis in lung cancer through mitochondrial pathway
por: Wang, Sumei, et al.
Publicado: (2020) -
Traditional Chinese medicine, Fuzheng Kang-Ai decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway
por: Li, Longmei, et al.
Publicado: (2017) -
Traditional Chinese medicine, Fuzheng Kang-Ai decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway
por: Li, Longmei, et al.
Publicado: (2021) -
The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study
por: Wan, Yue-Meng, et al.
Publicado: (2017)